Latest News

(UroToday.com) At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) session on optimizing personalized management of non-muscle invasive bladder cancer included a debate regarding the optimal therapy for BCG-unresponsive disease among patients that are not cystectomy candidates. Dr. Arjun Balar from NYU in New York made the argument for systemic therapy […]

(UroToday.com) The combination of cisplatin-based chemotherapy with immune checkpoint inhibitors has previously been extensively investigated in urothelial carcinoma. Using this combination in the neoadjuvant setting for patients with muscle-invasive urothelial carcinoma might improve pathological response but carries the risk of increased perioperative morbidity. At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Richard […]

(UroToday.com) Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Up to 50% of these patients are medically ineligible for cisplatin due to low performance status, renal dysfunction, or other medical comorbidities.  Immune checkpoint blockade is a first line therapeutic option in either platinum ineligible patients or carboplatin eligible patients whose […]

BACKGROUND Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment. METHODS We conducted a global, open-label, phase 3 trial of enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial carcinoma who had previously […]

(UroToday.com) Atezolizumab (anti–PD-L1) monotherapy is approved for cisplatin-ineligible patients who have locally advanced or metastatic urothelial carcinoma with PD-L1–expressing immune cells on ≥ 5% of the tumor area (IC2/3 per VENTANA SP142 IHC assay).1 The IMvigor130 primary analysis demonstrated a significant progression free survival benefit with atezolizumab plus platinum/gemcitabine (Arm A) versus placebo platinum/gemcitabine (Arm C) as first-line […]

(UroToday.com) In plenary presentation in the Progress and Promise in Treatment Personalization for Advanced Prostate Cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Karen Autio discussed ways in which we can harness the immune system to treat prostate cancer, emphasizing the role of immune checkpoint inhibitors in prostate […]

(UroToday.com) At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) session on optimizing personalized management of non-muscle invasive bladder cancer included a debate regarding the optimal therapy for BCG-unresponsive disease among patients that are not cystectomy candidates. Dr. Peter Black from Vancouver, British Columbia made the argument for intravesical therapy as […]

(UroToday.com) At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Dr. Kaelin provided the keynote lecture entitled “von Hippel-Lindau Tumor Suppressor Protein: Rosetta Stone for Kidney Cancer Pathogenesis and Treatment”.

(UroToday.com) Real-world data regarding treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) remain scarce due to the lack of a specific ICD-10 code for these patients. Using the Optum Research Database, which includes enrollment information and medical/pharmacy claims for over 73 million enrollees with commercial coverage and 8.3 million enrollees with Medicare, the authors created a […]

(UroToday.com) The case presented was that of a 54-year-old man with an extensive family history of cancer. His mother died from ovarian cancer, his father had prostate cancer and died of colon cancer, his brother developed kidney and prostate cancer, and his sister had breast and ovarian cancer. The patient had germline testing, which revealed […]